title: Opportunities and challenges of developing peptide drugs in the pharmaceutical industry.
authors.affiliation: Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 07110, USA.
authors.forename: Waleed
authors.initials: W
authors.lastname: Danho
authors.forename: Joseph
authors.initials: J
authors.lastname: Swistok
authors.forename: Wajiha
authors.initials: W
authors.lastname: Khan
authors.forename: Xin-Jie
authors.initials: XJ
authors.lastname: Chu
authors.forename: Adrian
authors.initials: A
authors.lastname: Cheung
authors.forename: David
authors.initials: D
authors.lastname: Fry
authors.forename: Hongmao
authors.initials: H
authors.lastname: Sun
authors.forename: Grazyna
authors.initials: G
authors.lastname: Kurylko
authors.forename: Leonid
authors.initials: L
authors.lastname: Rumennik
authors.forename: Joseph
authors.initials: J
authors.lastname: Cefalu
authors.forename: Gretchen
authors.initials: G
authors.lastname: Cefalu
authors.forename: Philip
authors.initials: P
authors.lastname: Nunn
mesh_terms: D015195:Drug Design; D004345:Drug Industry; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D010455:Peptides / Q000737:chemistry* / Q000627:therapeutic use; D044105:Receptor, Melanocortin, Type 4 / Q000737:chemistry
chemical_list: D010455:Peptides; D044105:Receptor, Melanocortin, Type 4